Epidermal growth factor receptor (EGFR) mutation testing and first-line treatment with gefitinib as a strategy in the treatment of patients with advanced non-small cell lung cancer (NSCLC).

Authors

G. Lopes

Johns Hopkins Singapore, Singapore, Singapore

G. Lopes , J. Segel , D. S. W. Tan , Y. Do , T. Mok , E. Finkelstein

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Phase ΙΙ study of gefitinib and inserted cisplatin plus docetaxel as a first-line treatment for advanced non-small cell lung cancer haboring an epidermal growth factor receptor activating mutation.

First Author: Shintaro Kanda

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Gefitinib as third-line re-challenge treatment in advanced NSCLC patients with EGFR activating mutation who benefited from first-line gefitinib treatment followed by second-line chemotherapy.

First Author: Yong Song

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials.

First Author: Chee Lee

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Circulating tumor DNA to guide furmonertinib monotherapy or combination therapy in advanced EGFR mutant non-small cell lung cancer (NSCLC): A randomized, open-label, multicenter study (FOCUS-C).

First Author: Wenfeng Fang